Meeting
2016 ASCO Annual Meeting
A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.
Authors
Philippe Armand
Dana-Farber Cancer Institute, Boston, MA
Philippe Armand , Margaret Ann Shipp , John Kuruvilla , Graham P Collins , Rod Ramchandren , John Timmerman , Anne Sumbul , Mary M. Ruisi , Kazunobu Kato , Stephen Maxted Ansell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02181738
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS7573)
DOI
10.1200/JCO.2016.34.15_suppl.TPS7573
Abstract #
TPS7573
Poster Bd #
128b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.
First Author: Robert W. Chen
Poster
2022 ASCO Annual Meeting
Sequential pembrolizumab (pembro) and chemotherapy (chemo) in newly diagnosed, early unfavorable, or advanced-stage classical Hodgkin lymphoma (cHL): The phase 2 KEYNOTE-C11 study.
First Author: Jane N. Winter
Poster
2019 ASCO Annual Meeting
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.
First Author: Christine Mauz-Körholz
Poster
2018 ASCO Annual Meeting
KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.
First Author: Christine Mauz-Korholz